COVID-19 vaccine in vials with maroon caps, developed by Pfizer, are now approved for use in children aged 6 months to 5 years, with 3 injections of 3µg per dose. The vaccine is 80.3% effective at preventing COVID-19.

Secretary-General of Thailand’s Food and Drug Administration (TFDA) Dr. Paisarn Dunkum said yesterday (Wednesday) that, on August 23rd, the TFDA subcommittee considering the registration of modern pharmacopoeia for humans, as a vaccine against the virus which causes COVID-19, approved the expansion of the use of Pfizer’s Comirnaty vaccine to include children aged 6 months to 5 years.

The company had previously allowed the use of the vaccine for auto-immune stimulation in people aged 12 years and older. The age range was extended to children between 5 and 11-years-old. Doses of the vaccine used in children were reduced to 10µg, with two doses of intramuscular vaccination 21 days apart.

For use in children aged 6 months to 5 years, 3µg of the vaccine will be used in three injections. The second injection is 3 weeks after the first and the third 8 weeks later.

More than 57 million people in Thailand have received at least one dose of vaccine against COVID-19, 31.6 million of whom already jabbed with boosters.